PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.79%
Revenue growth at 50-75% of AVGO's 11.10%. Martin Whitman would worry about competitiveness or product relevance.
7.87%
Gross profit growth at 50-75% of AVGO's 13.00%. Martin Whitman would question if cost structure or brand is lagging.
20.72%
EBIT growth below 50% of AVGO's 51.39%. Michael Burry would suspect deeper competitive or cost structure issues.
12.68%
Operating income growth under 50% of AVGO's 51.39%. Michael Burry would be concerned about deeper cost or sales issues.
24.76%
Net income growth under 50% of AVGO's 92.44%. Michael Burry would suspect the firm is falling well behind a key competitor.
24.49%
EPS growth under 50% of AVGO's 106.67%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
24.14%
Diluted EPS growth under 50% of AVGO's 107.14%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.22%
Share reduction more than 1.5x AVGO's 0.75%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.32%
Diluted share reduction more than 1.5x AVGO's 1.20%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
13.33%
Maintaining or increasing dividends while AVGO cut them. John Neff might see a strong edge in shareholder returns.
47.26%
OCF growth above 1.5x AVGO's 5.35%. David Dodd would confirm a clear edge in underlying cash generation.
47.49%
FCF growth above 1.5x AVGO's 5.63%. David Dodd would verify if the firm’s strategic investments yield superior returns.
47.46%
10Y revenue/share CAGR under 50% of AVGO's 573.88%. Michael Burry would suspect a lasting competitive disadvantage.
40.65%
5Y revenue/share CAGR under 50% of AVGO's 138.92%. Michael Burry would suspect a significant competitive gap or product weakness.
16.50%
3Y revenue/share CAGR under 50% of AVGO's 34.16%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
120.33%
10Y OCF/share CAGR under 50% of AVGO's 819.60%. Michael Burry would worry about a persistent underperformance in cash creation.
63.52%
Below 50% of AVGO's 291.05%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
18.07%
3Y OCF/share CAGR under 50% of AVGO's 71.74%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
128.52%
Below 50% of AVGO's 381.19%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
122.19%
5Y net income/share CAGR 1.25-1.5x AVGO's 109.80%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
425.94%
3Y net income/share CAGR above 1.5x AVGO's 109.19%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
12.26%
Below 50% of AVGO's 846.57%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
1.64%
Below 50% of AVGO's 244.66%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-4.74%
Negative 3Y equity/share growth while AVGO is at 17.80%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
681.02%
Dividend/share CAGR of 681.02% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
167.12%
Below 50% of AVGO's 717.49%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
64.37%
Below 50% of AVGO's 236.98%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
1.58%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-5.65%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
6.28%
Positive asset growth while AVGO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
10.11%
BV/share growth above 1.5x AVGO's 0.59%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
4.74%
We have some new debt while AVGO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
0.52%
We increase R&D while AVGO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-2.21%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.